Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
PlexBio Co., Ltd. (6572) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PlexBio Co., Ltd. TWD 2.71, price TWD 7.11, upside -61.9%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
PC
Thin data
Sep 24, 2026
PlexBio Co., Ltd.
6572 · TWOWeakest SetupStrongly overvalued and low quality.
!Fair value 2.71 TWD · Strongly overvalued (−62%)
!Quality 47/100
!Weak Growth (revenue 5y +4.6 %/yr)
!Loss-making · -49.2% net margin (TTM)
!negative free cash flow
!Trails peers (2/9)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch PlexBio Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 5.49 TWD – 13.00 TWD · fair‑value band 1.79 TWD – 3.39 TWD · the 7.11 TWD price screens above the 2.71 TWD fair value. As of Sep 24, 2026.
Follow PlexBio Co. in your weekly email
Every Wednesday you see whether PlexBio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects.
Show more
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Stock analysis
PlexBio Co., Ltd. (6572) currently trades at 7.11 TWD, while our model-based Fair Value estimate is 2.71 TWD, implying the stock looks roughly 162.3% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 1.79 TWD (bear) to 3.39 TWD (bull), the price of 7.11 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
PlexBio Co., Ltd. reported revenue of 127M TWD in FY2025 versus 125M TWD in FY2021, a compound +0.4%/yr. Reported net income was −62.5M TWD in FY2025.
Key figures
Market cap 859M TWD (≈ $27.0M) · P/S ratio 6.76 · EPS (TTM) −0.6000 TWD · Net margin −49.2% · Return on equity −18.2% · Return on assets (EBIT) −14.2% · Operating margin −44.4% · Revenue (TTM) 127M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −62%, 6572 screens richer than that median.
Fair Value models
Bear 1.79 TWD
Fair Value 2.71 TWD
Bull 3.39 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
1.50 TWD
2.01 TWD
3.00 TWD
51
All 1 models by family
Asset-Based
NCAV (Graham)
1.50 TWD
2.01 TWD
3.00 TWD
51
Notify me when 6572 reaches fair value
Put 6572 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
47/100
Of which business quality 47 · Market factors (momentum, volatility) 33
Profitability
6
Margins and returns on capital today
Quality Growth
28
Are margins and returns improving?
Cashflow
17
Earnings quality: real cash, not paper profit
Fin. Strength
75
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
27
Calm price path (market factor)
Momentum
47
Price trend over the last 3–12 months (market factor)
52W Momentum
16
Distance to the 52-week high (market factor)
Net Issuance
86
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
16/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−146.3% (2020) → −51.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
6572 screens 162% overvalued. Compare with Abbott Laboratories, →
Compare PlexBio Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $103.49 | $74.79 | −28% |
| Stryker Corporation SYK | $273.40 | $300.74 | +10% |
| Medtronic plc MDT | $89.30 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $44.62 | $49.08 | +10% |
| Edwards Lifesciences Corporation EW | $86.82 | $82.04 | −6% |
| Siemens Healthineers AG SHL | €37.21 | €35.22 | −5% |
| DexCom, Inc DXCM | $87.73 | $96.50 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.27 | $69.62 | +5% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥156.68 | ¥172.35 | +10% |
| Koninklijke Philips N.V PHIA | €21.85 | €15.32 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is PlexBio Co., Ltd. (6572) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2.71 TWD versus a price of 7.11 TWD, about −62% upside (overvalued).
What is the fair value of 6572?
Our model-based fair value for PlexBio Co., Ltd. is 2.71 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 7.11 TWD.
What is the quality score of 6572?
PlexBio Co., Ltd. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PlexBio Co., Ltd. (6572)?
Our model-based price target is the fair value of 2.71 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1.79 TWD, optimistic scenario 3.39 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the PlexBio Co., Ltd. stock forecast for 2026?
Our models put fair value at 2.71 TWD, about −62% upside versus a price of 7.11 TWD (overvalued). Cautious scenario 1.79 TWD, optimistic scenario 3.39 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of PlexBio Co., Ltd. (6572)?
PlexBio Co., Ltd. reported trailing-twelve-month revenue of about 127M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of PlexBio Co., Ltd. (6572)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PlexBio Co., Ltd. it is 2.71 TWD per share (as of Sep 24, 2026), against a price of 7.11 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is PlexBio Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6572 trades above its calculated fair value: price 7.11 TWD, fair value 2.71 TWD, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6572?
No. The price is what the market pays today (7.11 TWD); the fair value is what the company's own numbers justify (2.71 TWD). For PlexBio Co., Ltd. the two are 4.40 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is PlexBio Co., Ltd. worth?
The market values PlexBio Co., Ltd. at about 859M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 7.11 TWD; our models calculate a fair value of 2.71 TWD per share.
What do the bullish and bearish scenarios say about 6572?
Our models span a range for PlexBio Co., Ltd.: cautious scenario 1.79 TWD, base 2.71 TWD, optimistic 3.39 TWD per share (as of Sep 24, 2026, price 7.11 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PlexBio Co., Ltd. (6572)?
Balance-sheet figures for PlexBio Co., Ltd. (as of Sep 24, 2026): return on equity −18.2%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
Which stocks are comparable to PlexBio Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PlexBio Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 7.11 TWD, calculated fair value 2.71 TWD (−62%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6572 calculated?
We run PlexBio Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.71 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. PlexBio Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PlexBio Co., Ltd. (6572)?
The closing price on Sep 24, 2026 was 7.11 TWD. Our model-based fair value is 2.71 TWD, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PlexBio Co., Ltd. right now?
The price sits above even our optimistic bull case (3.39 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1.79 TWD to 3.39 TWD) leaves room in how you read the outcome.
Key figures of PlexBio Co., Ltd.
How large is the market capitalisation of PlexBio Co., Ltd. (6572)?
The market capitalisation of PlexBio Co., Ltd. is 859M TWD (≈ $27.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PlexBio Co., Ltd. (6572)?
The price-to-sales ratio of PlexBio Co., Ltd. is 6.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PlexBio Co., Ltd. (6572)?
Earnings per share at PlexBio Co., Ltd. are −0.6000 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PlexBio Co., Ltd. (6572)?
The net margin of PlexBio Co., Ltd. is −49.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PlexBio Co., Ltd. (6572)?
The return on equity (ROE) of PlexBio Co., Ltd. is −18.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PlexBio Co., Ltd. (6572)?
On an EBIT basis the return on assets of PlexBio Co., Ltd. is −14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PlexBio Co., Ltd. (6572)?
The operating margin of PlexBio Co., Ltd. is −44.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PlexBio Co., Ltd. (6572)?
Revenue at PlexBio Co., Ltd. is growing −27.4% versus a year earlier (3y avg −12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does PlexBio Co., Ltd. (6572) generate?
The free cash flow of PlexBio Co., Ltd. is −79.5M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does PlexBio Co., Ltd. (6572) hold?
PlexBio Co., Ltd. holds more cash than debt, 261M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PlexBio Co., Ltd. in the live analysis
One click puts PlexBio Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.